Inspire Medical Systems stock dropped 4.1% in morning trading after Bank of America downgraded the medical device maker to Underperform from Neutral and reduced its price target to $39 from $53. The analyst action, which sparked weakness before the market open, centers on what BofA described as an absence of a stable, consistent coding pathway that treatment centers can rely on when billing for procedures involving the Inspire V sleep apnea implant.
BofA flagged the lack of a clear reimbursement route for Inspire V as the main issue driving the downgrade. The firm indicated that an official CPT code for Inspire V is not expected before January 1, 2028 at the earliest, and cautioned it could take longer. That timeline, in BofA's view, materially raises the risk to near-term revenue and earnings estimates for the company.
The downgrade compounds a set of negative developments for Inspire that have emerged in recent weeks. Management revised the companys outlook for 2026, now projecting revenue in a range of $825 million to $875 million, which the company said represents a 4% to 10% decline compared with 2025. The updated guidance also includes an expected diluted EPS range of $0.07 to $0.62, reflecting the ongoing uncertainty tied to coding and reimbursement.
Company leadership has pointed to several specific disruptions driving the weaker outlook. Management cited the phase-out of a key CPT code and interference from the WISeR program as factors that complicated Medicare reimbursement for Inspire V cases. In prepared remarks, CEO Tim Herbert said, "we are continuing to work with key stakeholders to implement solutions that will resolve the coding and reimbursement uncertainty for Inspire V," and added, "we expect the challenges caused by this uncertainty to persist through the balance of 2026."
The setback for Inspire is notable given the otherwise constructive tone in U.S. equities on the day. The S&P 500 was up 0.7%, the Dow Jones gained 0.8%, and the NASDAQ advanced 0.7%, making Inspire's decline a clear outlier versus the broader market. The shares have fallen sharply over the past year, down more than 70%, and were trading at $43.84, just above their 52-week low of $39.61 at the time of the move.
Analysts and investors now see several overlapping factors pressuring the stock: a fresh sell-side downgrade with a below-market price target, a substantially revised full-year revenue outlook, and a persistent, structural uncertainty related to reimbursement coding for the Inspire V device. The companys latest guidance cut and the first-quarter loss underscore how central the reimbursement situation has become to the investment case.
For investors and market participants, clarity around coverage and payment for Inspire V remains the principal near-term catalyst to reassess the company's trajectory. Until such clarity arrives, the combination of slower revenue expectations and ongoing coding ambiguity is likely to continue shaping investor sentiment and valuation of the shares.
Market context and positioning
Inspire's share move highlights how industry-specific operational issues - in this case, coding and reimbursement - can drive idiosyncratic performance even when broad markets are advancing. Health care providers, payers, and device makers that rely on predictable billing frameworks are directly affected by delays or changes to coding, which can in turn influence revenue recognition and the timing of procedures.